Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Gynecologic 5Breast 4Genitourinary 2Gastrointestinal 2Head & Neck 1CNS 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
paclitaxel poliglumex × Genitourinary × Clear all
NCT00459810 2017-04-28

Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
21 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00446836 2016-03-17

Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Completed
29 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡